Navigation Links
Sinapis Pharma Completes Phase I Trial
Date:7/11/2011

JACKSONVILLE, Fla., July 11, 2011 /PRNewswire/ -- Sinapis Pharma, Inc. is pleased to announce that it has completed its first clinical trial in the development of its lead drug for the treatment of stroke and traumatic brain injury.  The Phase I trial entitled " A Phase 1, Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetics of Oral and Intravenous Administration of Methamphetamine Hydrochloride in Healthy Volunteers" was conducted at Prism Research in St. Paul, MN.

This was a single-center, open-label, randomized, two-period, two-treatment, two-sequence, single dose, crossover study of the safety and pharmacokinetics of oral and IV administration of methamphetamine HCl in six healthy volunteers.  Subjects were randomized 1:1 to receive a single oral dose of methamphetamine HCl (5 mg Desoxyn® tablet) or a single IV dose of methamphetamine HCl (5 mL of 0.5 mg/mL methamphetamine HCl injection infused over one hour for a total dose of 2.5 mg), and then crossed over to the other treatment (i.e., IV or oral dose, respectively) after a 10 day washout period.  Subjects received a single dose of study drug on Day 1 of each of the two treatment periods.

The trial successfully demonstrated the safety of an IV infusion of Methamphetamine and produced the IV infusion pharmacokinetics needed to initiate Phase IIa clinical studies in stroke patients.

Sinapis plans to initiate its Phase IIa trial in stroke patients before year end.

Dr Donald Picker, Sinapis CEO, said  "We are very pleased  and excited to complete the next step in the development of this drug for stroke and traumatic brain injury patients. We are eager to begin the proof of principle trials in these very important indications where there are currently no effective treatments."

Sinapis Pharma, Inc. (www.sinapispharma.com) is an early stage biotechnology company whose lead compound methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models.


'/>"/>
SOURCE Sinapis Pharma, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Laszlo Radvanyi, Ph.D. Joins Genesis Biopharma Scientific and Medical Advisory Board
2. SCOLR Pharma, Inc. Announces Final Closing of Private Placement
3. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
4. Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience
5. PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation
6. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
7. Genesis Biopharma Conference Call and Webcast Reminder
8. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
9. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
10. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
11. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... advanced technology applications, has announced a facility expansion to accommodate its rapid growth. ... feet of new workspace and renovation of the existing areas. The expansion includes, ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... manufacturers to re-engineer their control technology again and again. METTLER TOLEDO has released ... machine manufacturers. The videos illustrate how integration of the ACT350 into Siemens and ...
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation Fertility scientists’ work ... Association of Bioanalysts (AAB) and the College of Reproductive Biology (CRB) today and ... commitment to excellence in clinical laboratory services and regulations. , “We are ...
(Date:5/18/2017)... Mass. (PRWEB) , ... May 18, 2017 , ... ... the procedure on April 28, 2017 at the Prince Of Wales Private Hospital. ... cervical disc at level C6-C7. The patient failed conservative treatments prior to undergoing ...
Breaking Biology Technology:
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
Breaking Biology News(10 mins):